Displaying drugs 14801 - 14825 of 15217 in total
CRA_16847
Experimental
UK-500001
UK-500,001 has been used in trials studying the treatment of Pulmonary Disease, Chronic Obstructive.
Investigational
Ado-P-Ch2-P-Ps-Ado
Experimental
Matched Iupac: … 9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)sulfanylidene-lambda5-phosphanyl]oxy})phosphinic acid …
Brigimadlin
Investigational
Matched Iupac: … triazaspiro[indole-3,12'-tetracyclo[7.6.0.0^{2,7}.0^{10,14}]pentadecane]-1',3',5',7'-tetraene-5'-carboxylic acid …
(3,4-Dihydroxy-Phenyl)-Triphenyl-Arsonium
Experimental
Immucillin-G
Experimental
Talviraline
Talviraline has been used in trials studying the treatment of HIV Infections.
Investigational
4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
Experimental
Dexetimide
A muscarinic antagonist that has been used to treat neuroleptic-induced parkinsonism. Benzetimide is the (-)-enantimorph of dexetimide.
Withdrawn
Mephenoxalone
Experimental
DG051
DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4...
Investigational
Matched Description: … attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and …
A-98881
Experimental
BMS-564929
BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.
Experimental
Displaying drugs 14801 - 14825 of 15217 in total